Filter by
Filter by
Patterns of Local-Regional Failure after IMRT or Passive Scattering PT with Concurrent Chemotherapy for NSCLC.
Published in the Red Journal, this retrospective analysis by MD Anderson group reviewed 212 patients treated with IMRT and PT, most (152 [72%]) had no failure...
Clinical outcomes of intensity modulated proton therapy and concurrent chemotherapy in esophageal carcinoma (EC).
19 patients with EC treated with IMPT concurrently with chemotherapy. Clinical complete response was achieved in 84%.
The most common grade 3 acute toxicities...
High-dose Intensity-modulated proton therapy versus Standard-dose Intensity-modulated RadIation therapy for esophageal squamous cell carcinoma (HI-SIRI): study protocol for a randomized controlled clinical trial.
This is a study protocol details a randomized trial taking place in Thailand with multiple centers comparing IMPT and IMRT for stage II–IVA squamous thoracic...
Cardiopulmonary Toxicity Following Intensity-Modulated Proton Therapy (IMPT) Versus Intensity-Modulated Radiation Therapy (IMRT) for Stage III Non-Small Cell Lung Cancer.
163 consecutively treated patients with biopsy-proven, stage III NSCLC who received IMPT (n = 35, 21%) or IMRT (n = 128, 79%) were analyzed in this study...
Proton and photon radiotherapy in stage III NSCLC: Effects on hematological toxicity and adjuvant immune therapy.
This study reported the incidence of lymphopenia in 271 stage III NSCLC patients treated with IMPT (n=71) vs IMRT (n=200) and concurrent chemotherapy. The...